KCNH2 and pancreatic ductal adenocarcinoma: In a different setting (pancreatic ductal adenocarcinoma), we found an association and a physical interaction between Kv11.1 and EGFR, raising the possibility of designing combined treatment schedules, also involving Kv11.1 blockers (Lastraioli et al., 2015c).